Načítá se...
The use of natalizumab for multiple sclerosis
Natalizumab is a monoclonal antibody that acts as an α4 integrin antagonist to prevent leukocyte trafficking into the central nervous system. It is US Food and Drug Administration (FDA) approved for the treatment of relapsing–remitting multiple sclerosis (RRMS). Natalizumab demonstrated high efficac...
Uloženo v:
| Vydáno v: | Neuropsychiatr Dis Treat |
|---|---|
| Hlavní autoři: | , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Dove Medical Press
2017
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5499927/ https://ncbi.nlm.nih.gov/pubmed/28721050 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/NDT.S114636 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|